Tuesday, 20 Mar 2018

You are here

Probenecid Benefits Heart Failure

In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation. This concept was further studied in 20 patients with heart failure with reduced ejection fraction where probenecid was shown to improve cardiac function after just one week of probenecid treatment.

Probenecid is thought to exert its effects via calcium channel activation by transient receptor potential vanilloid 2.

Patients were treated in a randomized, double‐blind, crossover design. Clinical performance data were collected and parallel laboratory studies assessed murine cardiomyocytes exposed to probenecid or control treatments.

Probenecid therapy significantly increased fractional shortening by versus placebo (P=0.007) and improved diastolic function compared with placebo.

In vitro probenecid increased myofilament force generation (P<0.05) and calcium sensitivity (P<0.01) compared with control.

These findings suggest that myocardial benefits to probenecid treatment may be related to direct effects on calcium channel signaling rather than the indirect effects of serum urate on renal and vascular function. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease. 

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

New BSR 2017 Gout Guidelines (Best of 2017)

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.